Exclusion criteria
vitreous macular traction syndrome, mellitus, allergy, dementia, cataract, mental disorder, malignant tumor, conjunctival inflammation, epiretinal
DIABETIC RETINOPATHY, ALLERGY, COMPLICATIONS, DRY EYE, CATARACT, MYOPIA, STAPHYLOMA, MALIGNANT TUMOR, MACULAR EDEMA, OCULAR INFECTION
History of allergy to mydriatic agents and eye surface anestheticsPresence of vitreous macular traction syndrome, macular edema, epiretinal membrane, myopia with posterior staphyloma, diabetic retinopathy, conjunctival inflammation, ocular infection, severe dry eye, grade 3 or higher Emery-Little grade cataract, and posterior capsule opacificationHistory or complications of a malignant tumor. However, patients with a history of malignant tumor that has not relapsed for more than 5 years were not excludedDiagnosis of dementia or mental disorder with ongoing treatmentDiabetes mellitus (HbA1c [NGSP]> 10.0%)Hypertension (systolic ≥ 180 mmHg and/or diastolic ≥ 110 mmHg) that is difficult to control even with oral treatmentAny of the following on a screening blood sampling test:
Aspartate aminotransferase and alanine aminotransferase: more than three times the upper limit of the facility standard valueSerum creatinine: more than 1.5 times the upper limit of the facility standard valueOngoing treatment with ethambutol hydrochloride and/or amiodarone hydrochlorideOngoing pregnancy, breastfeeding, or possible or planned pregnancy during the trial periodParticipation in other clinical trialsUnder investigational responsibility (shared) judged by doctors to be inappropriate for participation in this trial